Ozempic vs. Wegovy vs. Mounjaro: What’s the difference?

In this article:

• Main differences
• Comparing FDA approval
• Efficacy
• Dosing and administration
• Insurance coverage and cost
• Side effects and considerations
• Making informed decisions

In this article

• Main differences
• Comparing FDA approval
• Efficacy
• Dosing and administration
• Insurance coverage and cost
• Side effects and considerations
• Making informed decisions

If you have Type 2 diabetes or obesity, you have probably heard about these medications used to treat one or both conditions: Ozempic, Wegovy, and Mounjaro. These brand-name medications belong to different but overlapping drug classes and work similarly to stimulate insulin production, resulting in lower blood sugar and reduced appetite. Ozempic and Mounjaro are FDA approved to treat diabetes, while Wegovy is an FDA-approved weight loss medication.

Although these medications are used for similar purposes, they differ in several ways, including their active ingredients, potential side effects, and likelihood of insurance coverage.

What are the main differences between Ozempic, Wegovy, and Mounjaro?

Ozempic, Wegovy, and Mounjaro are similar drugs, but they are not identical to one another. The main differences when comparing these injectable medications are their active ingredients, drug classifications, and FDA-approved purposes.

• Active ingredient. Ozempic and Wegovy are both brand-name forms of semaglutide, their active ingredient. Mounjaro’s active ingredient is tirzepatide.
• Drug classification. Ozempic and Wegovy’s active ingredient, semaglutide, targets glucagon-like peptide-1 (GLP-1) receptors and is classified as a GLP-1 receptor agonist. In contrast, Mounjaro’s active ingredient, tirzepatide, targets GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. This categorizes it as a dual GIP/GLP receptor agonist.
• Approved uses. Ozempic and Mounjaro are FDA-approved treatments for blood sugar control. Wegovy is an approved weight management medication.

Comparing FDA approval: Ozempic vs. Wegovy vs. Mounjaro

Ozempic and Mounjaro are FDA-approved to treat Type 2 diabetes, while Wegovy is approved for chronic weight management. All three medications have additional FDA-approved uses, although some indications vary by formulation.

FDA-approved diabetes treatment

According to manufacturer Novo Nordisk, Ozempic is FDA approved for three uses in adults with Type 2 diabetes:

• Improving blood sugar levels alongside diet and exercise
• Reducing the risk of major cardiovascular events, including heart attack and stroke, in adults with Type 2 diabetes and established heart disease
• Reducing the risk of worsening kidney function, kidney failure, and cardiovascular death in adults with Type 2 diabetes and chronic kidney disease (CKD)

Mounjaro, made by Eli Lilly, is FDA approved to improve blood sugar control in adults and children ages 10 and older with Type 2 diabetes. It is also approved to reduce the risk of major cardiovascular events, including heart attack, stroke, and cardiovascular death, in adults with Type 2 diabetes who are at high risk for these events.

FDA-approved weight management treatment

Wegovy, also made by Novo Nordisk, is FDA approved for the following uses:

• Long-term weight management in adults with obesity or adults who are overweight and have at least one weight-related health condition, such as high blood pressure or high cholesterol
• Long-term weight management in children ages 12 and older with obesity (injectable Wegovy only)
• Reducing the risk of heart attack, stroke, and cardiovascular death in adults with established heart disease who are overweight or have obesity
• Treating metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease, in adults with moderate to advanced liver scarring but without cirrhosis (injectable Wegovy only)

Wegovy is available as a once-weekly injection and a once-daily oral tablet. Although both forms are approved for weight management and cardiovascular risk reduction in certain adults, some FDA-approved uses apply only to the injection.

Ozempic and Mounjaro are sometimes prescribed off-label for weight loss. However, neither medication is FDA-approved specifically for chronic weight management.

FDA-approved age populations

FDA-approved age ranges also differ among these medications. Ozempic is approved for adults ages 18 and older. Mounjaro is approved for Type 2 diabetes in adults and children ages 10 and older, although its cardiovascular indication applies only to adults. Injectable Wegovy is approved for weight management in adults and children ages 12 and older, while oral Wegovy is approved for adults only.

Which medication is most effective for weight loss?

Though all three of these medications are effective for weight loss, “tirzepatide works better,” says Cynthia Odogwu, MD, a family and lifestyle medicine physician in Maryland. The increased effectiveness is likely because tirzepatide products like Mounjaro target two metabolic hormone receptors — GIPs and GLP-1s — compared to semaglutide products like Ozempic and Wegovy, which only target GLP-1s.

Let’s take a look at clinical trials on these drugs:

• In a 40-week study comparing the effectiveness of tirzepatide and semaglutide in patients with Type 2 diabetes, tirzepatide users lost an average of 2-6 kg (4.4-13.2 lbs) more than semaglutide users, depending on the dosage. Higher doses resulted in more weight loss.
• In a 68-week clinical study comparing Wegovy (semaglutide) with a placebo, about 69% of Wegovy users lost 10% or more of their body weight compared to 12% of placebo users who lost about the same body weight percentage.
• In a cohort study of 18,386 adults with overweight or obesity, the average reduction in body weight after three months of treatment for tirzepatide users was 5.9% compared to 3.6% for semaglutide users.

As for comparing Ozempic and Wegovy? “Both these medications have semaglutide as the active ingredient. They are just different brands,” emphasizes Marisa Landetta, RD, a registered dietitian specializing in weight management in Lehi, Utah. Ultimately, the weight loss effectiveness of Ozempic versus Wegovy comes down to dosage.

It’s important to remember that Ozempic and Mounjaro are meant for diabetes rather than weight loss. Wegovy has the same active ingredient as Ozempic and is an FDA-approved weight loss drug. Tirzepatide, the active ingredient in Mounjaro, is also available as a weight loss drug under the brand name Zepbound. Another GLP-1 receptor agonist that has been approved for weight loss is called Saxenda (liraglutide). Ultimately, you should seek personalized medical advice for the best weight loss treatment for you.

Dosing and administration

Ozempic, Wegovy, and Mounjaro are all administered via once-weekly subcutaneous self-injection, with Ozempic and Wegovy also available in the form of an oral tablet. They are all intended for long-term use. They all start at a lower dose that is gradually increased depending on the treatment response.

Injectable Ozempic dosage starts at 0.25 mg once weekly and can be increased to a maximum of 2 mg weekly. Oral Ozempic starts at 1.5 mg once daily and can be increased to a maximum of 9 mg daily. Injectable Wegovy dosage also starts at 0.25 mg once weekly and can be increased to a maximum of 2.4 mg weekly. Oral Wegovy starts at 1.5 mg once daily and can be increased to a maximum of 25 mg daily. Mounjaro dosage starts at 2.5 mg injected once weekly and can be increased to a maximum of 15 mg weekly.

Not everyone reaches the maximum dosage, as many healthcare providers prefer to keep patients at the lowest effective dose for their needs. It is essential to work with your healthcare provider to determine whether you should decrease the dosage to a maintenance level after reaching a healthy weight.

Insurance coverage and cost

The out-of-pocket costs of Ozempic, Wegovy, and Mounjaro vary based on retail prices, insurance coverage, and reason for treatment. Mounjaro and Ozempic are generally more likely to be covered by Medicare and private health insurance plans when prescribed for Type 2 diabetes. Wegovy may also be covered for certain FDA-approved uses, although some plans require prior authorization. Additionally, eligible Medicare beneficiaries may qualify for Wegovy at a reduced cost through the Medicare GLP-1 Bridge Program. Even with insurance coverage, out-of-pocket costs vary by plan.

Without insurance or discounts, the average retail cost for a one-month supply of these medications varies by dosage, form of administration, and pharmacy. SingleCare Wegovy, Ozempic, or Mounjaro coupons may help reduce the cash price by hundreds of dollars.

Side effects and considerations

Ozempic, Wegovy, and Mounjaro share similar side effects, but Dr. Odogwu says side effect frequency is lower with tirzepatide than semaglutide.

The most common side effects for all three are gastrointestinal issues, including:

• Nausea
• Vomiting
• Diarrhea
• Constipation

Other possible side effects include:

• Indigestion
• Bloating
• Fatigue
• Injection site reactions

Hypoglycemia, or low blood sugar, is a serious side effect of all three drugs and warrants urgent medical attention.

Side effects vary by drug and dosage, and this is not a complete list of side effects. Higher doses are associated with increased incidence and severity of side effects. It’s important to consult your healthcare provider if you experience severe side effects after starting one of these medications.

Making informed decisions

Ozempic, Wegovy, and Mounjaro are similar drugs, but they’re not identical. Ozempic and Wegovy both contain semaglutide, but they’re approved for different uses: diabetes treatment and weight loss, respectively. Ozempic and Mounjaro have different active ingredients but share the same approved uses: blood sugar management in Type 2 diabetes.

“Although you can find pretty helpful information online, I do recommend still getting lab work and discussing with your provider which option is best for you, since they will be able to take into account factors including other health conditions, medications, and insurance coverage,” says Landetta.

Ultimately, consulting with a prescribing healthcare provider ensures that you are receiving the best treatment for your weight loss goals and circumstances, including your insurance coverage. And if you’re struggling to navigate the costs of these expensive drugs, a healthcare provider can offer more affordable alternatives or point you toward ways to save with copay assistance programs or drug manufacturer discount offerings.